A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
Shanghai Henlius Biotech
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Adaptimmune
Innate Pharma
LG Chem
Incyte Corporation
Pfizer
Pfizer
MacroGenics
University of Virginia
Incyte Corporation
Shattuck Labs, Inc.
Checkpoint Therapeutics, Inc.
Vincerx Pharma, Inc.
Molecular Templates, Inc.
Inhibrx Biosciences, Inc
RemeGen Co., Ltd.
Xencor, Inc.
Pliant Therapeutics, Inc.
University of California, San Francisco
Atreca, Inc.
University of Florida
Apexigen America, Inc.
Fate Therapeutics
Cantargia AB
Fate Therapeutics
Xencor, Inc.
Herlev Hospital
Advaxis, Inc.
Xencor, Inc.
Ludwig Institute for Cancer Research
PACT Pharma, Inc.
Genocea Biosciences, Inc.
EMD Serono
Pfizer
Incyte Corporation
Shanghai Junshi Bioscience Co., Ltd.
Incyte Corporation